Skip to main content

Preparing newborn screening for the future: a collaborative stakeholder engagement exploring challenges and opportunities to modernizing the newborn screening system


Background and objectives

Projections that 60 transformative cell and gene therapies could be approved by the U.S. Food and Drug Administration (FDA) within 10 years underscore an urgent need to modernize the newborn screening (NBS) system. This study convened expert stakeholders to assess challenges to the NBS system and propose solutions for its modernization.


NBS stakeholders (researchers, clinicians, state NBS leaders, advocates, industry professionals, and current/former advisory committee members) participated in one of five mixed-stakeholder panel discussions. Prior to panels, participants completed a survey in which they reviewed and ranked NBS challenges generated from relevant literature. During panels, participants deliberated on challenges and explored potential solutions. Pre-panel survey data were analyzed descriptively. Data from panel discussions were analyzed using a rapid qualitative analysis.


Median scores of the ranked challenges (1 = most important) reveal the top three most important barriers to address: critical missing data for NBS decision-making (Median = 2), burden on state NBS laboratories (Median = 3), and the amount of time required for state-level implementation of screening for new conditions (Median = 4). Panel discussions were rooted in recurring themes: the infant’s well-being should be the focal point; the transformative therapy pipeline, although undeniably positive for individuals with rare diseases, is a threat to NBS capacity; decisions about modernizing NBS should be evidence-based; additional financial support is required but not sufficient for modernization; and modernization will require participation of multiple NBS stakeholders. This final overarching theme is reported in depth, including expertise, coordination, and collaboration challenges facing NBS and novel approaches to oversight, partnership, and coordination that were suggested by participants.


This study engaged representatives from multiple stakeholder groups to generate potential solutions to challenges facing NBS in the United States. These solutions provide a rich starting point for policy makers and other stakeholders who desire to maximize the impact of new transformative therapies for babies, families, and society.

Peer Review reports


Public health decision-making is inevitably complicated because of the involvement of multiple stakeholders, such as federal, state, and local government, researchers, health care providers, advocates, and the public at large. In the United States, history has demonstrated the challenges of unifying and mobilizing stakeholders when a public health system needs to adapt to external forces such as advances in technology or the onset of new infectious diseases [1, 2]. Newborn Screening (NBS) presents a classic example of a complex public health system needing to adapt to best serve its intended beneficiaries: babies and families. Over the past 50 years, NBS has saved or improved the lives of countless babies by identifying rare, but serious medical conditions presymptomatically and referring them for immediate treatment. However, the system in its current state is unprepared to adapt to an approaching opportunity and challenge: the advent of a growing number of transformative therapies targeting rare conditions. The number of conditions that are likely to be candidates for NBS once they have an associated therapy threatens to overwhelm the system unless stakeholder partnerships are leveraged and processes are changed.

NBS in the United States requires coordination between state and federal governments, which increases the complexity of implementation and change. The federal government has oversight over the national Recommended Uniform Screening Panel (RUSP), and the process of adding a condition to the RUSP involves contributions of both government and nongovernment stakeholders. Conditions are recommended for the RUSP by the Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC), a committee consisting of 15 voting members appointed by the Secretary of Health and Human services (10 individuals with relevant expertise and 5 individuals who represent federal agencies that fund or support aspects of NBS, such as Centers for Disease Control and Prevention [CDC]) and additional representatives from organizations that intersect with infant and child health (e.g., American Academy of Pediatrics). At the state level, legislatures, departments of public health, NBS laboratories, and advisory committees are key players in decisions about adding RUSP conditions to each state’s screening panel, and screening and follow-up procedures for each condition vary by state.

Other NBS stakeholders include rare disease advocates and policymakers, who worked together to enact the federal legislation that made NBS a public health program and who continue to advocate to fund and enhance the program on federal and state levels. Families and advocacy groups also play an important role in advocating for conditions to be added to the RUSP and state NBS panels. Additionally, prior to implementing NBS for new conditions, there is a need for researchers to collect natural history data, academic and industry sponsors to develop and test treatments, and private companies and public institutions to develop diagnostic tests and screening protocols. Finally, health care providers have the critical role of performing diagnostic testing, communicating with families about their child’s condition, connecting babies to treatment, and providing long-term follow-up services.

Despite successful collaboration of these stakeholders to build and sustain NBS, the system now faces a disruptive, albeit positive, force: the transformative therapy pipeline for rare conditions. At least 60 cell and gene therapies are projected to be approved by the Food and Drug Administration (FDA) by 2030, and FDA recently reported more than 1000 Investigational New Drugs (INDs) applications for cell and gene therapy treatments are currently on file [3, 4]. NBS could ensure timely access to these treatments. However, the need for federal approval and state implementation of screening for so many conditions would almost certainly overwhelm the current system. Collecting sufficient evidence to meet the criteria for RUSP approval [5] can take years. And once a condition is added to the RUSP, there is wide variability in how long it takes each state to approve a condition for its panel and allocate funding for implementation. For example, X-linked adrenoleukodystrophy was nominated to be considered for the RUSP in 2012 and added to the RUSP in 2016 [6], but currently only 23 states screen for the condition [7]. Thus, it can take years to achieve nationwide screening for even one condition. The degree to which this problem could be exacerbated by the transformative therapy pipeline is sobering and underscores the critical need to engage all NBS stakeholders in modernizing the system.

In this study we convened a series of multistakeholder panels to engage NBS experts and advocates in collectively prioritizing challenges to NBS modernization and proposing solutions to enable realizing the potential of transformative therapies within the NBS system.



We employed a multistakeholder expert panel approach to address three aims:

  • Aim 1. Prioritize and explore the most impactful barriers to realizing the potential of transformative therapies within the NBS system.

  • Aim 2. Generate potential solutions to barriers of NBS modernization.

  • Aim 3. Rate the feasibility, acceptability, and sustainability of implementation of solutions identified across the panels.

The first two aims were addressed through multistakeholder panel discussions described herein. The third aim was addressed by a follow-up survey completed by panel participants, which is reported elsewhere [8].

Study design

We modeled our approach after several methodologies that have implemented group discussion among heterogeneous stakeholders for brainstorming or problem-solving [9,10,11,12,13]. Focus groups, which are traditionally and intentionally composed of individuals with similar experiences, are an established method for eliciting stakeholder perspectives [14]. However, when the objective is systems change, discourse between stakeholders with diverse priorities and experiences can result in a more holistic understanding of the breadth of a problem and the generation of more viable solutions [15]. Accordingly, we selected mixed-stakeholder discourse as the preferred methodology to explore barriers and solutions to modernizing the NBS system. Participants in each of our panels represented five NBS stakeholder groups. During the panel sessions we did not aim to achieve thematic saturation or consensus, but instead to facilitate initial cross-stakeholder consideration of challenges and brainstorm solutions, with the expectation that ongoing engagement of a larger number of stakeholders would be needed to refine solutions.

Research activities were framed around this transformative therapy scenario: It is 2030—ten years from today. Thirty or more new transformative gene or cell therapies have been approved by the FDA to treat monogenic, non-oncology rare disorders. Please consider the following assumptions. These assumptions may not reflect future reality but will be useful to frame our upcoming group discussion.

  • Each treats a different genetic disorder.

  • Each has a valid screening assay that is not prohibitively costly.

  • The therapies are curative or significantly disease modifying if given early in life, but much less or not effective if given later.

  • The longer-term risks and duration of efficacy are unknown.

  • Assume that the cost of the therapies will be completely covered by payers (e.g., insurance, Medicaid).


NBS experts (i.e., individuals highly experienced with some aspect of NBS) were nominated by a consortium of funders and RTI researchers and invited to participate. We aimed to recruit approximately 50 participants, representing 10 individuals from each of 5 stakeholder groups:

  1. 1.

    NBS researchers or clinicians

  2. 2.

    State NBS directors or program leaders

  3. 3.

    Representatives of patient advocacy organizations

  4. 4.

    Representatives of pharmaceutical or diagnostic companies

  5. 5.

    Current and former members of federal or state advisory committees


Prior to initiating data collection, the investigators conducted a literature scan to identify and summarize challenges to NBS that are reflected in published literature; these are available as Additional File 1. Data collection was conducted between December 2020 and January 2021 and included three phases.

Pre-panel survey

An online survey included basic demographic questions and a rating activity where participants indicated their familiarity with and expertise in various aspects of NBS. Additionally, participants were asked to rank a list of NBS challenges stemming from the summarization of the published literature. Participants were asked to indicate which challenges were the most important to address to achieve NBS for 30 new disorders in 10 years, based on the context of the transformative therapy scenario (Additional File 1).

Multistakeholder expert panels

We then convened five mixed-stakeholder expert panels of 7–10 participants per panel. Each 90-min panel discussion was conducted virtually using Zoom, a web conferencing platform. Audio and video were recorded. Investigators used a semistructured interview guide to address the following:

  • Exploration of each panel’s prioritized challenges to NBS modernization. Investigators displayed the results of the pre-panel ranking of challenges for each of the panels (i.e., each panel viewed their own panel members’ aggregated ranking results). The moderator asked participants to elaborate on the most highly prioritized challenges and to make a case for any challenges that were missing from the list.

  • Solutions. Participants were guided to explore potential solutions to the most highly prioritized challenges and to consider the acceptability, feasibility, and sustainability of those solutions based their own expertise, priorities, and experience with NBS.

Post-panel survey

Approximately one month after each panel discussion, participants were asked to respond to a second online survey, reported in a separate article.

Participants were asked to draw on all of their NBS experiences and perspectives during their participation (i.e., not attempt to reflect the experiences or attitudes of one stakeholder group). Each participant was offered a $100 gift card for participation. Some participants declined the incentive. This study was determined to be exempt by the RTI International Institutional Review Board (IRB).


Pre-panel survey data were analyzed using descriptive statistics. Multistakeholder panel discussions were analyzed qualitatively by investigators who moderated and took notes during all five panels (HLP and SMA, respectively) and a third analyst (KAP). The investigators, all of whom have expertise in qualitative methods, conducted a rapid assessment process, which is a team-based qualitative inquiry that uses triangulation and iterative data analysis to quickly develop an understanding of the data [16]. Rapid qualitative analyses are increasingly used for health services and implementation research in which there is a need to quickly, but rigorously, synthesize findings for use in policy and practice decision-making [17,18,19,20]. Investigators implemented the rapid assessment using a matrix-based approach that included audio-recordings and detailed notes from each panel discussion [17, 21,22,23]. Specifically, recordings and notes were used to develop structured summaries of each panel. Preliminary coding of the structured summaries was completed using codes derived from the moderator guide. The third analyst reviewed transcripts to quality check the summaries and the preliminary coding, transferred summaries into a data matrix organized by the challenges and solutions proposed by each panel, and incorporated supplementary notes and quotes. Using a consensus process, the analysis team reviewed the matrix to refine the coding into meaningful categories and compare challenge and solution themes across panels [17, 24]. The study Principal Investigator (DB) reviewed the analysis and provided an additional expert perspective on the interpretation of the summary findings.

Here we describe primary themes that emerged; this report is not inclusive of all challenges and solutions that were discussed.



Forty-two experts consented to participate. Participant demographics and self-identified stakeholder group are reported in Table 1. Stakeholders’ ages ranged from between 35 years and 75 years or older. Most stakeholders (71%) had a doctorate degree. All were from the United States or Canada.

Table 1 Participant Demographics

Ranking of challenges in pre-panel survey

Aggregated results of the ranking activity, across all panels, are reported in Table 2. A median ranking score was calculated for each of the challenges, with lower score indicating higher importance of the challenge for addressing the transformative therapy scenario. Of the nine challenges, critical missing data for NBS decision-making was the highest ranked challenge (Median = 2, range 1–9), followed by burden on state NBS laboratories (Median = 3, range 1–8) and the amount of time required for state-level implementation of screening for new conditions (Median = 4, range 1–7).

Table 2 Ranking the most important challenge to address to modernize NBS (n = 41)*

Overarching themes

Although all panel discussions were framed around the same hypothetical scenario, the content of discussions varied by nature of being prompted based on highly ranked challenges from the pre-panel survey, facilitated by a semi-structured guide, and largely driven by participants. Across all panel discussions, stakeholders expressed shared attitudes and beliefs around which they framed their discussion of NBS’s challenges and solutions. Overarching themes and exemplary quotes can be found in Table 3.

Table 3 Overarching Panel Themes: Exemplar Quotes

The infant’s well-being should be the focal point for the NBS system as new solutions are developed and implemented

Stakeholders reinforced their shared desire to connect babies to life-saving treatments and shared frustration at current and potential future barriers to this objective (Table 3, Quote 3.1.).

The transformative therapy pipeline is a threat to NBS system capacity, which already suffers from inefficiencies and delays because of burden on federal and state systems

Stakeholders acknowledged that the time-consuming nature of evidence review by the ACHDNC and implementation of new conditions by states is not scalable in the context of the transformative therapy pipeline (Table 3, Quotes 3.2.a. and 3.2.b.).

Decisions about how to modernize the NBS system should be evidence-based

Stakeholders valued evidence-based decision-making. They emphasized that critical data are missing in the current system and that these missing data further threaten the ability of NBS to adapt to anticipated therapeutic advances. Stakeholders thus underscored the importance of solutions that result in data generation using standardized approaches. They also endorsed ongoing assessment of the evidence generated by such approaches, and evidence-based refinements or revisions to the system (Table 3, Quote 3.3.).

Additional financial support is required but is not sufficient for successful NBS modernization

Stakeholders reinforced the vital need to provide sufficient financial support at all levels of the system: to allow for critical data to be collected and analyzed; to make it feasible for the ACHDNC to more rapidly review a larger number of conditions; for states to implement screening; and for states to support and improve their follow-up programs. But while financial resources are critically needed, the stakeholders agreed that an infusion of funding would not address NBS challenges unless implemented along with other changes to the system (Table 3, Quote 3.4.).

Successful modernization will require the participation and coordination of multiple stakeholders and organizations in the development, implementation, and ongoing evaluation of new solutions

Participant discussion revealed a shared understanding that NBS is a multifaceted system that requires engagement and collaboration among stakeholders with differing motivations and norms, including federal agencies, researchers, policymakers, treatment facilities, state NBS laboratory and follow-up teams, patient advocates, and the public. Successful NBS requires a broad range of expertise, and diverse stakeholders must be part of planning, implementation, and evaluation of new approaches to modernize NBS modernization (Table 3, Quote 3.5.).

This final overarching theme of collaboration, coordination and expertise-sharing was reflected in much of the panel deliberations, as described below. Exemplary quotes that address the theme of expertise and coordination challenges can be found in Table 4.

Table 4 Expertise and Coordination Challenges: Exemplar Quotes

Expertise and coordination challenges

State/federal coordination challenges

As a national public health service, NBS requires leadership from the federal level and coordination across 50 states and territories. Stakeholders described the RUSP as an “unfunded mandate,” underscoring the challenge of federally initiated policies driving decision-making for state implementation, but without accompanying financial support or policies to standardize implementation and follow-up. For each condition added to the RUSP, individual state laboratories must expend time and resources on preparatory activities such as verifying screening methodologies and developing standard operating procedures (SOPs) for screening and follow up before implementing a screening approach (Table 4, quote 4.1.).

As a result, there can be wide variability in the rollout of screening for new conditions across states and the possibility that babies in neighboring states will be screened for a different set of conditions. Longitudinal data, particularly around child outcomes after follow-up, are often missing because of the variability in state data collection requirements and lack of coordination between the medical specialists who provide treatment and the state follow-up program. Stakeholders also described lack of federal guidance and coordination as a contributor to gaps in follow-up data and lack of standardized follow-up practices across states. Finally, stakeholders acknowledged that there is often a lack of coordination and communication between federal agencies that collect data and make decisions regarding the funding and implementation of NBS, such as FDA, CDC, and the Health Resources & Services Administration.

Expertise-related implementation challenges

A successful NBS program requires a broad range of expertise. Stakeholders described how screening, confirmatory testing, and follow-up have become more complex with the advent of new testing methodologies and technology advances (e.g., molecular techniques for confirmatory testing, genotype-specific treatments), causing a need for expanding expertise and a more specialized workforce (Table 4, Quote 4.2.). Additionally, as NBS expands, follow-up personnel and institutions that provide treatment and management require additional expertise in many rare conditions and across all organ systems.

Simultaneously, NBS has been impacted by staffing issues associated with high turnover rates at state laboratories, in some cases attributed to lower salaries as state employees compared to academic or industry laboratories. NBS is also one of many competing public health priorities that state laboratories are managing. Highly competent laboratory staff and follow-up personnel are necessary for the advent of 30 new conditions being added to the RUSP, and stakeholders doubted states’ ability to recruit and maintain the requisite staffing and expertise to implement so many conditions.

Public education and awareness challenges

NBS stakeholders also described challenges related to public awareness and education. Stakeholders acknowledged NBS as a highly impactful public health initiative but recognized that the impact and benefits of NBS are not widely known by the public or by state legislature. Furthermore, the public perception of NBS has been threatened by recent lawsuits and legislative battles over privacy and allowable uses of dried blood spots collected for NBS (Table 4, Quote 4.3.).

Stakeholders described a need to improve public knowledge of NBS and build appreciation for the benefits and impact of NBS. There was an emphasis on expanding conversations beyond the typical stakeholders and reaching those who have the greatest stake in NBS: families.

Novel approaches to oversight, partnership, and collaboration

Stakeholders’ proposed solutions to these challenges led to discussions of intersecting topics, including expertise-sharing, capacity-building, and good communication, addressing a broader theme of leveraging stakeholder collaboration to modernize NBS. Additional concepts explored improved integration of federal, state, and nongovernment systems. Exemplary quotes addressing the theme of novel approaches to oversight, partnership, and collaboration can be found in Table 5.

Table 5 Novel Approaches to Oversight, Partnership, and Collaboration: Exemplar Quotes

Expand collaborative pilot studies to test implementation of screening

Stakeholders proposed expanding pilot studies as a way to collect data or increase state laboratory capacity before adding new conditions to states’ panels, which may improve the feasibility of screening for multiple new conditions at once. One proposed model was to support several large or diverse states in conducting collaborative, multi-state pilot studies to obtain missing data on a new condition, or set of conditions, to support evidence-based decision-making prior to adding conditions to the RUSP. This model would leverage cross-state collaboration and information-sharing and likely involvement of federal and academic partners (Table 5, Quote 5.1.).

Another proposed model was for individual states to offer screening for conditions soon to be added to the RUSP, prior to adding them to the state’s screening panel, through a consented research study similar to existing pilot studies such as Early Check (North Carolina) or ScreenPlus (New York) [25, 26]. This model would particularly leverage collaboration between state and academic partners to provide access to screening for some babies prior to full state implementation. Collection of critical missing data would be an important objective, with an understanding that it would be more challenging to achieve representative participation for research that requires parental permission (i.e., not opt-out) for newborn participation.

Use of either of these pilot study models may allow for new academic/public health partnerships to emerge while generating critical data and providing opportunities for states to use research funding (e.g., from NIH) to expand their expertise, obtain necessary equipment, develop and evaluate screening and confirmatory testing SOPs, and test follow-up procedures during pilot implementation.

Develop expertise-sharing models

Stakeholders proposed ways in which some screening methodologies could be moved out of state laboratories to locations with the necessary expertise to conduct screening or second-tier testing. These approaches would maintain state oversight and encourage resource sharing while alleviating implementation burdens on state laboratories.

One proposed solution was the creation of regional NBS laboratories with expertise and capacity in particular methodologies. This model, in which multiple states would send blood spots to the regional laboratory, was proposed to either span all of NBS or to be used for laboratory methodologies that require technological expertise not available in most states. This model would allow states to specialize in some conditions and associated laboratory methodologies and become a regional laboratory for other states while outsourcing other conditions for which they have insufficient equipment or expertise. This regionalization approach was anticipated to potentially streamline processes while reducing overall costs and burden associated with NBS in each state (Table 5, Quote 5.2.a.).

Another proposed solution was to create or expand collaboration between state NBS programs and universities and academic medical centers. For example, states could outsource screening for certain conditions to university laboratories, and NBS could become more closely aligned with academic medical centers such that states draw from screening, confirmatory testing, interpretation, data analysis and reporting, and follow-up expertise of academic partners rather than bringing new expertise into state laboratories (Table 5, Quote 5.2.b.). These expertise-sharing solutions may increase state-level resources and capacity and support systematic data collection and analysis, especially as screening and confirmation approaches become more complex.

Develop a public-private partnership to increase resources and reduce burden on the NBS system

Stakeholders described the creation of a consortium of industry, state and federal government, academic partners, and other stakeholders as a possible facilitator of other proposed solutions (e.g., expansion of pilot studies and expertise-sharing models). They suggested that a public-private partnership could provide scientific leadership, oversight, and funding for NBS implementation, ongoing data collection, and reporting of outcomes (Table 5, Quote 5.3.). For example, private companies involved in therapeutics could fund pilot studies or aspects of screening implementation and in turn be benefited by funding associated with identification of babies who need the treatment they have developed. Private funding could support academic-state partnership models such as regional laboratories or conducting NBS screening and follow-up through academic medical centers, either as the sole funder or supplemented by federal funding streams. Short- and long-term follow-up could also be enhanced by such partnerships, for example by incorporating private genetic counseling organizations into NBS.

Other innovative solutions

Such partnerships may provide the resources and expertise needed to pilot even more radical innovations to the system in response to the rapid development of new treatment approaches for rare conditions. One example was the idea of collaborative pilot studies where industry professionals, academic institutions, and states provide screening for a condition with the goal of offering the parents of affected newborns immediate enrollment of their baby in clinical trials. Another example was the idea that conditions would be automatically added to state NBS at the time of new treatment approval by FDA, either as a pilot or as part of the full state panel. Finally, some stakeholders suggested a “conditional RUSP,” where conditions would have a much lower bar for RUSP approval, with the expectation that data would be obtained during implementation and regularly reviewed to determine whether the condition should remain on the RUSP (Table 5, Quote 5.4.),

Improve education and public opinion about NBS

Stakeholders suggested opportunities to increase awareness and educate the public about NBS through collaboration of parents/patient advocates, federal and state programs, and other stakeholders. Some recommended reframing rare diseases identified through NBS as a collective public health burden, rather than each new NBS condition presenting a standalone example when it comes to justifying costs or benefits of screening (Table 5, Quote 5.5.a.).

Stakeholders also suggested that promoting the benefits of NBS through a public relations campaign could prove beneficial for advocacy and “making a case” for screening to state legislators (Table 5, Quote 5.5.b.). Such a campaign could incorporate the data generated as part of other solutions proposed by stakeholders, such as data on family perspectives of NBS and results of cost-benefit analyses.


NBS is at a critical inflection point. Although the NBS system has been successful at achieving its goals, obvious challenges and inefficiencies will cause major hurdles and delays when lifesaving therapies become available for numerous disorders that are not yet part of the RUSP. The findings from our multistakeholder panels provide important input to inform efforts to modernize NBS in the United States. Participants identified multifaceted challenges that have been previously reported, particularly vital missing data [6, 27,28,29], inadequate resources [30,31,32,33], and processes that are ill-equipped for rapid or large-scale change [30, 31, 33, 34]. Although many of the challenges to NBS are exacerbated by insufficient funding [28, 30, 32, 33], our results suggest that NBS modernization will require systemwide change that includes, but extends beyond, strategic financial investments to support RUSP approval and screening implementation.

Developing and implementing acceptable and efficacious solutions will require new and strengthened collaborations and capacity-building that cannot easily be achieved through the existing NBS system. It is vital that multiple stakeholders are active in developing solutions, and that those stakeholders remain engaged as solutions are implemented and evaluated [35]. Innovations must work within existing federal and state policies or be addressed through legislative changes. The federal government is unable to mandate state public health practice (with a few notable exceptions), as evidenced by the RUSP being a recommended rather than mandated panel, with states having agency in determining their own screening practices. To that end, participants described innovative ways to leverage strengths, expertise, and resources of stakeholder groups to benefit the overall system.

Participants envisioned both practical and innovative approaches to future NBS. Some of these require only modest change and could be achieved through active collaboration and support of existing NBS state, federal, and academic partners. One example is developing new approaches to regional expertise and expertise sharing. This would allow states to identify their priorities for internal capacity building and share that expertise with others in the region, while relying on reciprocal screening arrangements with other laboratories. The expansion of pilot studies is another approach to develop new collaborations that would result in important data while allowing states an opportunity to implement screening for conditions that are not yet on the RUSP. However, maximizing impact will require addressing multiple limitations, such as the lack of required, standardized collection of natural history and outcomes data that can be used to inform future NBS decision making. It was suggested that more standardized data collection could be facilitated by cross-agency coordination on the federal level.

Other approaches suggested by participants, such as implementing a public-private partnership, have been considered in the NBS context [33] and could dramatically change the way NBS is led, funded, and conducted in the United States if implemented on a larger scale. Such an approach brings exciting opportunities for innovation but also potential conflicts of interest that must be carefully examined and mitigated. NBS stakeholders’ focal point on the infant’s well-being provides a guiding principle against which to deliberate and negotiate on conflicts of interest, in that conflicts that potentially negatively impact the infant and family should be considered differently than those that do not.

The focus on enhancing infant well-being also provides stakeholders with a shared framework to evaluate the potential benefits and harms of other proposed (and yet to be proposed) innovations to NBS. For example, the intriguing concept of linking NBS pilots to the drug development process highlights competing potential benefits and harms to infants and their families. Newborn identification makes trial participation available as an option for more parents of newborns with rare conditions, which may provide hope and a potential for a better outcome for the child. Additionally, conducting NBS pilots to identify children who can be recruited to ongoing clinical trials would very likely speed up the drug development process, since recruitment of infants with rare disorders is time consuming and costly for trial sponsors [25, 36]. This could result in faster access to lifesaving and approved therapies for children around the world. And yet it should not be assumed that trial participation will be acceptable and appealing for all parents, and moreover that all children will meet inclusion criteria or that all families will have the resources (such as parent time, ability to miss work, the ability to travel to sites) necessary to make trial participation possible. Most important is the need to avoid therapeutic misconception (i.e., a failure to appreciate that the purpose of clinical research is to produce generalizable knowledge, regardless of the potential for individual benefit) in the NBS system [37]. Clinical trials do not provide treatments to affected children, but rather test an experimental drug to determine whether it is safe and whether it works.

Another innovative solution was the concept of conditional RUSP approval, whereby conditions could be approved using a less stringent set of criteria but then periodically be reevaluated based on emerging data from state implementation. Such an approach permits the implementation of a “learning system” that could support infant well-being through enhanced access to disease modifying therapies in the presymptomatic or early symptom stage. And yet conditional approval based on a lower threshold of evidence could result in challenges such as unacceptably high false positive or false negative rates. It could lead to increased uncertainty about which infants need treatment, and when (i.e., based on insufficient natural history data and unexpected disorder heterogeneity), potentially exposing infants to unneeded treatment-related risk and parents to anxiety and burden. Finally, it may be challenging for states to remove a condition from the state’s panel once screening for that condition begins, even if emerging evidence leads to the conditional approval being revoked. Stakeholders across the system should be engaged in this type of deliberation to weigh the potential benefits, harms, and limitations of approaches to NBS modernization.

The findings generated by our multistakeholder panels are an important first step in support of system change to pave the way for next generation NBS. While our study was focused on the NBS system in the United States, the findings will have some applicability to NBS in other countries. The themes that emerged do not reflect consensus among stakeholders; rather, we present concepts that emerged from their discourse on the future of NBS in the context of the transformative therapy scenario. It was not feasible to compare themes by stakeholder group because many participants had current or past experiences in more than one stakeholder group. It will be important for future research and engagement efforts to include stakeholders with broad expertise and experiences to develop detailed implementation objectives and procedures for NBS in the United States. Additional efforts should examine the applicability of the findings to non-U.S. countries.

Availability of data and materials

Because of the nature of this work, the small sample, and assurances of confidentiality provided to participants in the consent form, transcripts of panel discussions cannot be shared. We can provide aggregated, de-identified ranking results from each of the five pre-panel surveys upon request.



Advisory Committee on Heritable Disorders in Newborns and Children


Centers for Disease Control and Prevention


U.S. Food and Drug Administration


Investigational New Drug


Institutional Review Board


newborn screening


Recommended Uniform Screening Panel


standard operating procedure


  1. Safran C, Bloomrosen M, Hammond WE, Labkoff S, Markel-Fox S, Tang PC, et al. Toward a national framework for the secondary use of health data: an American medical informatics association white paper. J Am Med Inform Assoc. 2007;14(1):1–9.

    Article  Google Scholar 

  2. Schuchat A, Team CC-R. Public health response to the initiation and spread of pandemic COVID-19 in the United States, February 24-April 21, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(18):551–6.

    Article  CAS  Google Scholar 

  3. MIT NEWDIGS FoCUS Project. Updated projection of US durable cell and gene therapies product-indication approvals based on December 2019 development pipeline: Ongoing pipeline modeling by the MIT NEWDIGS FoCUS team projects 10X growth from July 2020 levels, but with large uncertainties. MIT Center for Biomedical Innovation; 2020. Report No.: 2020F207-v051.

  4. Bryan WW. FDA/CBER Office of Tissues and Advanced Therapies (OTAT) selected topics. American Society of Gene & Cell Therapy (ASGCT) Liaison Meeting; 2020.

  5. Kemper AR, Green NS, Calonge N, Lam WK, Comeau AM, Goldenberg AJ, et al. Decision-making process for conditions nominated to the recommended uniform screening panel: statement of the US Department of Health and Human Services Secretary's advisory committee on heritable disorders in newborns and children. Genet Med. 2014;16(2):183–7.

    Article  Google Scholar 

  6. Kemper AR, Brosco J, Comeau AM, Green NS, Grosse SD, Jones E, et al. Newborn screening for X-linked adrenoleukodystrophy: evidence summary and advisory committee recommendation. Genet Med. 2017;19(1):121–6.

    Article  Google Scholar 

  7. ALD Alliance. Newborn screening 2021 [Available from:]

  8. Bailey DB, Porter KA, Andrews SM, Raspa M, Gwaltney AY, Peay HL. Expert Evaluation of Strategies to Modernize Newborn Screening in the United States. JAMA Netw Open. 2021;4(12):e2140998.

  9. Torok RD, Li JS, Kannankeril PJ, Atz AM, Bishai R, Bolotin E, et al. Recommendations to enhance pediatric cardiovascular drug development: report of a multi-stakeholder think tank. J Am Heart Assoc. 2018;7(4).

  10. Aziz PF, Berger S, Kowey P, Krucoff M, Lopez-Anderson M, Michelson E, et al. The second annual think tank on prevention of sudden cardiac death in the Young: developing a rational, reliable, and sustainable national health care resource. A report from the cardiac safety research consortium. Am Heart J. 2018;202:104–8.

    Article  Google Scholar 

  11. Morain SR, Whicher DM, Kass NE, Faden RR. Deliberative engagement methods for patient-centered outcomes research. Patient. 2017;10(5):545–52.

    Article  Google Scholar 

  12. Bentley C, Peacock S, Abelson J, Burgess MM, Demers-Payette O, Longstaff H, et al. Addressing the affordability of cancer drugs: using deliberative public engagement to inform health policy. Health Res Policy Syst. 2019;17(1):17.

    Article  Google Scholar 

  13. O'Sullivan TL, Corneil W, Kuziemsky CE, Toal-Sullivan D. Use of the structured interview matrix to enhance community resilience through collaboration and inclusive engagement. Syst Res Behav Sci. 2014;32(6):616–28.

    Article  Google Scholar 

  14. Grønkjær M, Curtis T, De Crespigny C, Delmar C. Analysing group interaction in focus group research: impact on content and the role of the moderator. Qualitative Studies. 1970;2(1):16–30.

    Article  Google Scholar 

  15. Ladeji EO. Multi-stakeholder engagement in health services research. J Comp Eff Res. 2018;7(6):517–21.

    Article  Google Scholar 

  16. Beebe J. Rapid assessment process: an introduction. 1st ed. Walnut Creek, CA: AltaMira Press; 2001.

    Google Scholar 

  17. Hamilton A, editor Qualitative methods in rapid turnaround health services research. VA HSR&D Cyberseminar Spotlight on Women’s Health; 2013; Online.

  18. Koenig CJ, Abraham T, Zamora KA, Hill C, Kelly PA, Uddo M, et al. Pre-implementation strategies to adapt and implement a veteran peer coaching intervention to improve mental health treatment engagement among rural veterans. J Rural Health. 2016;32(4):418–28.

    Article  Google Scholar 

  19. Zuchowski JL, Chrystal JG, Hamilton AB, Patton EW, Zephyrin LC, Yano EM, et al. Coordinating care across health care systems for veterans with gynecologic malignancies: a qualitative analysis. Med Care 2017;55 Suppl 7 Suppl 1:S53-S60.

  20. Moreau JL, Cordasco KM, Young AS, Oishi SM, Rose DE, Canelo I, et al. The use of telemental health to meet the mental health needs of women using Department of Veterans Affairs Services. Womens Health Issues. 2018;28(2):181–7.

    Article  Google Scholar 

  21. Abraham TH, Finley EP, Drummond KL, Haro EK, Hamilton AB, Townsend JC, et al. A method for developing trustworthiness and preserving richness of qualitative data during team-based analysis of large data sets. Am J Eval. 2021;42(1):139–56.

    Article  Google Scholar 

  22. Halcomb EJ, Davidson PM. Is verbatim transcription of interview data always necessary? Appl Nurs Res. 2006;19(1):38–42.

    Article  Google Scholar 

  23. Vindrola-Padros C, Johnson GA. Rapid techniques in qualitative research: a critical review of the literature. Qual Health Res. 2020;30(10):1596–604.

    Article  Google Scholar 

  24. Averill JB. Matrix analysis as a complementary analytic strategy in qualitative inquiry. Qual Health Res. 2002;12(6):855–66.

    Article  Google Scholar 

  25. Bailey DB Jr, Gehtland LM, Lewis MA, Peay H, Raspa M, Shone SM, et al. Early check: translational science at the intersection of public health and newborn screening. BMC Pediatr. 2019;19(1):238.

    Article  Google Scholar 

  26. Wasserstein M, Caggana M, Gelb MH, Goldenberg A, Kelly N, Matern D, et al. ScreenPlus: a comprehensive, dynamic, multi-disorder newborn screening pilot program. Mol Genet Metab 2020;129(2).

  27. Goldenberg AJ, Comeau AM, Grosse SD, Tanksley S, Prosser LA, Ojodu J, et al. Evaluating harms in the assessment of net benefit: a framework for newborn screening condition review. Matern Child Health J. 2016;20(3):693–700.

    Article  Google Scholar 

  28. Prosser LA, Grosse SD, Kemper AR, Tarini BA, Perrin JM. Decision analysis, economic evaluation, and newborn screening: challenges and opportunities. Genet Med. 2013;14(8):703–12.

    Article  Google Scholar 

  29. Riley C, Wheeler A. Assessing the fragile X syndrome newborn screening landscape. Pediatrics. 2017;139(Suppl 3):S207–s15.

    Article  Google Scholar 

  30. (CDC) CfDCaP. Assessment of current practices and feasibility of routine screening for critical congenital heart defects - Georgia, 2012. MMWR Morb Mortal Wkly Rep. 2013;62(15):288–91.

    Google Scholar 

  31. Kellar-Guenther Y, McKasson S, Hale K, Singh S, Sontag MK, Ojodu J. Implementing statewide newborn screening for new disorders: U.S. Program Experiences. International Journal of Neonatal Screening. 2020;6(2):35.

    Article  Google Scholar 

  32. Peterson C, Grosse SD, Glidewell J, Garg LF, Van Naarden BK, Knapp MM, et al. A public health economic assessment of hospitals' cost to screen newborns for critical congenital heart disease. Public Health Rep. 2014;129(1):86–93.

    Article  Google Scholar 

  33. Mann S. Insights in public health: newborn screening saves babies using public/private partnerships. Hawai'i journal of medicine & public health : a journal of Asia Pacific Medicine & Public Health. 2015;74(12):415–8.

    Google Scholar 

  34. Downing GJ, Zuckerman AE, Coon C, Lloyd-Puryear MA. Enhancing the quality and efficiency of newborn screening programs through the use of health information technology. Semin Perinatol. 2010;34(2):156–62.

    Article  Google Scholar 

  35. Bailey DB Jr, Zimmerman SJ. The future of newborn screening: why and how partnerships will be needed for success. N C Med J. 2019;80(1):28–31.

    PubMed  Google Scholar 

  36. Park CH, Winglee M, Kwan J, Andrews L, Hudak ML. Comparison of recruitment strategy outcomes in the National Children's study. Pediatrics. 2017;140(2).

  37. Henderson GE, Churchill LR, Davis AM, Easter MM, Grady C, Joffe S, et al. Clinical trials and medical care: defining the therapeutic misconception. PLoS Med. 2007;4(11):e324.

    Article  Google Scholar 

Download references


We are grateful to the study participants who contributed time and expertise to inform the study findings. We would like to recognize the support of Drs. Melissa Raspa and Angela Gwaltney of RTI International for their input in the development of the study and analysis of findings, respectively, and of Ms. Christine Hill of RTI International for her support in coordinating study logistics. We also thank the Consortium of Funders: Orchard Therapeutics, Sarepta Therapeutics, Travere Therapeutics, BioMarin, and the EveryLife Foundation for Rare Diseases.


The study was funded by a Consortium consisting of Orchard Therapeutics, Sarepta Therapeutics, Travere, BioMarin, and the EveryLife Foundation.

Author information

Authors and Affiliations



DBB and HLP contributed to the acquisition of this work. HLP led conception and design of the reported aspects of the study, with significant contributions from KAP and SMA. HLP and SMA collected study data. KAP led rapid qualitative data analysis, with contributions from HLP and SMA (quality check) and DBB (interpretation). SMA and KAP contributed equally to leading the writing of the manuscript. All authors contributed to writing the manuscript and have approved the final text. DBB is the principal investigator and oversaw all aspects of the research.

Although input was obtained from the Consortium of funders at each stage of the research process, the research team at RTI International (inclusive of all authors) was fully responsible for final decisions about study methodology and the content of this manuscript.

Corresponding author

Correspondence to Holly L. Peay.

Ethics declarations

Ethics approval and consent to participate

The RTI International IRB exempted this study from IRB review (STUDY00021366) under category 2 (Tests, Surveys, Interviews, Public Observation), criteria 2ii (Any disclosure of the human participants’ responses outside the research would not reasonably place the participants at risk of criminal or civil liability or be damaging to the participants’ financial standing, employability, educational advancement, or reputation). This study is not under federal oversight; thus, the IRB used 45 CFR 46 as the ethical framework to guide the review. This study was conducted in accordance with the Declaration of Helsinki. Informed consent to participate was obtained from all participants.

Consent for publication

Informed consent to participate and publish these data was obtained from all participants. No identifying information is included in the manuscript.

Competing interests

In addition to funding for this project, SMA, KAP, DBB, and HLP disclose research funding from Janssen Pharmaceuticals and Asuragen, each of which support projects funded through RTI International.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional File 1:

Hypothetical scenario and challenges from the literature

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Andrews, S.M., Porter, K.A., Bailey, D.B. et al. Preparing newborn screening for the future: a collaborative stakeholder engagement exploring challenges and opportunities to modernizing the newborn screening system. BMC Pediatr 22, 90 (2022).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: